BriaCell Therapeutics - BCTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 791.09%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.02
▼ -0.13 (-6.05%)

This chart shows the closing price for BCTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BriaCell Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCTX

Analyst Price Target is $18.00
▲ +791.09% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for BriaCell Therapeutics in the last 3 months. The average price target is $18.00, with a high forecast of $18.00 and a low forecast of $18.00. The average price target represents a 791.09% upside from the last price of $2.02.

This chart shows the closing price for BCTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in BriaCell Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
10/3/2023HC WainwrightLower TargetBuy ➝ Buy$25.00 ➝ $20.00Low
2/24/2023HC WainwrightReiterated RatingBuy$25.00Low
2/14/2022HC WainwrightInitiated CoverageBuy$25.00Low
(Data available from 4/21/2019 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/24/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/23/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/21/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
BriaCell Therapeutics logo
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Read More

Today's Range

Now: $2.02
Low: $2.01
High: $2.29

50 Day Range

MA: $2.94
Low: $2.02
High: $3.75

52 Week Range

Now: $2.02
Low: $2.01
High: $7.59

Volume

41,777 shs

Average Volume

72,512 shs

Market Capitalization

$32.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Frequently Asked Questions

What sell-side analysts currently cover shares of BriaCell Therapeutics?

The following Wall Street sell-side analysts have issued reports on BriaCell Therapeutics in the last twelve months: HC Wainwright.
View the latest analyst ratings for BCTX.

What is the current price target for BriaCell Therapeutics?

1 Wall Street analysts have set twelve-month price targets for BriaCell Therapeutics in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 791.1%. HC Wainwright has the highest price target set, predicting BCTX will reach $18.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $18.00 for BriaCell Therapeutics in the next year.
View the latest price targets for BCTX.

What is the current consensus analyst rating for BriaCell Therapeutics?

BriaCell Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BCTX will outperform the market and that investors should add to their positions of BriaCell Therapeutics.
View the latest ratings for BCTX.

What other companies compete with BriaCell Therapeutics?

How do I contact BriaCell Therapeutics' investor relations team?

BriaCell Therapeutics' physical mailing address is 3RD FLOOR BELLEVUE CENTRE 235-15TH STR, WEST VANCOUVER A1, V7T 2X1. The company's listed phone number is (604) 921-1810 and its investor relations email address is [email protected]. The official website for BriaCell Therapeutics is www.briacell.com. Learn More about contacing BriaCell Therapeutics investor relations.